These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33870103)

  • 1. "I felt like a TRIO champion": end-user perspectives on their role as co-designers of multi-purpose technologies.
    Agot K; Lutnick A; Shapley-Quinn MK; Ahmed K; Okello T; van der Straten A;
    Gates Open Res; 2020; 4():163. PubMed ID: 33870103
    [No Abstract]   [Full Text] [Related]  

  • 2. "We are not the same": African women's view of multipurpose prevention products in the TRIO clinical study.
    Shapley-Quinn MK; Manenzhe KN; Agot K; Minnis AM; van der Straten A
    Int J Womens Health; 2019; 11():97-107. PubMed ID: 30799959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.
    Minnis AM; Roberts ST; Agot K; Weinrib R; Ahmed K; Manenzhe K; Owino F; van der Straten A;
    AIDS Behav; 2018 Aug; 22(8):2662-2673. PubMed ID: 29560570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Female and male partner perspectives on placebo Multipurpose Prevention Technologies (MPTs) used by women in the TRIO study in South Africa and Kenya.
    Wagner LD; Minnis AM; Shea J; Agot K; Ahmed K; van der Straten A
    PLoS One; 2022; 17(5):e0265303. PubMed ID: 35551318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention.
    van der Straten A; Agot K; Ahmed K; Weinrib R; Browne EN; Manenzhe K; Owino F; Schwartz J; Minnis A;
    J Int AIDS Soc; 2018 Mar; 21(3):e25094. PubMed ID: 29600595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa.
    Minnis AM; Krogstad E; Shapley-Quinn MK; Agot K; Ahmed K; Danielle Wagner L; van der Straten A;
    Sex Reprod Health Matters; 2021 Dec; 29(1):1927477. PubMed ID: 34224341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engaging study participants in interpreting results: lessons from the TRIO study in Kenya and South Africa.
    Agot K; Minnis AM; Manenzhe K; Browne EN; Ahmed K; Okello T; van der Straten A
    Int J Womens Health; 2019; 11():395-403. PubMed ID: 31372060
    [No Abstract]   [Full Text] [Related]  

  • 8. End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa.
    Weinrib R; Minnis A; Agot K; Ahmed K; Owino F; Manenzhe K; Cheng H; van der Straten A
    AIDS Behav; 2018 Jan; 22(1):133-145. PubMed ID: 29052018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of end-user research to inform future multipurpose prevention technologies in sub-Saharan Africa: a scoping review.
    Bhushan NL; Ridgeway K; Luecke EH; Palanee-Phillips T; Montgomery ET; Minnis AM
    Front Reprod Health; 2023; 5():1156864. PubMed ID: 37325244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa.
    Minnis AM; Browne EN; Boeri M; Agot K; van der Straten A; Ahmed K; Weinrib R; Mansfield C
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):394-403. PubMed ID: 30633040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights for Implementation Science From 2 Multiphased Studies With End-Users of Potential Multipurpose Prevention Technology and HIV Prevention Products.
    Minnis AM; Montgomery ET; Napierala S; Browne EN; van der Straten A
    J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 3():S222-S229. PubMed ID: 31764258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferences, educational messaging, and demand creation channels for multipurpose-prevention technologies (MPTs) among women in South Africa.
    Mataboge P; Mthimkhulu N; Kutywayo A; Martin CE; Mazibuko M; Kwatsha K; Makalela N; Briedenhann E; Butler V; Bothma R; Mullick S
    BMC Public Health; 2023 Oct; 23(1):2090. PubMed ID: 37880628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring user and stakeholder perspectives from South Africa and Uganda to refine microarray patch development for HIV PrEP delivery and as a multipurpose prevention technology.
    Ismail A; Magni S; Katahoire A; Ayebare F; Siu G; Semitala F; Kyambadde P; Friedland B; Jarrahian C; Kilbourne-Brook M
    PLoS One; 2023; 18(8):e0290568. PubMed ID: 37651432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray patch for HIV prevention and as a multipurpose prevention technology to prevent HIV and unplanned pregnancy: an assessment of potential acceptability, usability, and programmatic fit in Kenya.
    Gachigua SG; Karuga R; Ngunjiri A; Jarrahian C; Coffey PS; Kilbourne-Brook M; Otiso L
    Front Reprod Health; 2023; 5():1125159. PubMed ID: 37168102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative Findings on MPT Attribute Preferences from the CUPID Study (MTN-045).
    Bhushan NL; Musara P; Hartmann M; Stoner MCD; Shah SR; Nabukeera J; Rukundo I; Mutero P; Lewis MA; Piper J; Shapley-Quinn MK; Etima J; Minnis AM
    J Int AIDS Soc; 2022 Oct; 25(10):e26024. PubMed ID: 36254362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How might we motivate uptake of the Dual Prevention Pill? Findings from human-centered design research with potential end users, male partners, and healthcare providers.
    Nyagah W; Segal K; Feltham J; Ash A; Major J; Masani M
    Front Reprod Health; 2023; 5():1254953. PubMed ID: 38023531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective acceptability of a multipurpose technology (MPT) implant in preclinical development to prevent HIV and unplanned pregnancy: Qualitative insights from women end users and health care providers in South Africa and Zimbabwe.
    Nkomo S; Makoni W; Shapley-Quinn MK; Luecke E; Mbatsane E; Manenzhe K; Ahmed K; Johnson LM; Mahaka I; van der Straten A
    PLoS One; 2023; 18(5):e0285711. PubMed ID: 37195918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study.
    Mack N; Evens EM; Tolley EE; Brelsford K; Mackenzie C; Milford C; Smit JA; Kimani J
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19157. PubMed ID: 25224616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study.
    Mukherjee J; Rawat S; Ul Hadi S; Aggarwal P; Chakrapani V; Rath P; Manchi P; Aylur S; Malhotra S; Keane M; Gangaramany A
    JMIR Res Protoc; 2024 Feb; 13():e47700. PubMed ID: 38324364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.